Welcome to our dedicated page for Pharmacielo news (Ticker: PCLOF), a resource for investors and traders seeking the latest updates and insights on Pharmacielo stock.
PharmaCielo Ltd. (PCLOF) generates frequent news as a Canada‑headquartered, globally oriented medical cannabis company with core operations in Colombia. As the parent of PharmaCielo Colombia Holdings S.A.S., which it describes as Colombia’s premier cultivator and producer of dried flower and medicinal‑grade cannabis extracts, the company regularly issues updates on trading status, financings, operational progress and regulatory developments.
News coverage for PharmaCielo often includes quarterly and year‑end financial results, with details on revenue trends, gross profit, adjusted EBITDA and net loss, as well as commentary on cost reductions and efficiency measures such as streamlining operations and right‑sizing cultivation capacity. Releases also describe working capital conditions, debenture offerings, related‑party bridge loans and the use of common shares to settle amounts owing or interest on secured debentures.
Investors following PCLOF news will also see corporate governance and regulatory items, including changes to the company’s auditor, adjustments to its financial year‑end, and information about cease trade orders, revocations and reinstatement to trading on the TSX Venture Exchange. The company’s communications further highlight commercial milestones, such as the use of its pharma‑grade API in a cannabidiol product selected by the State Government of São Paulo in Brazil, and commentary on Colombian regulatory resolutions affecting THC inventory timelines.
This page brings together these financial, corporate and operational announcements so readers can review PharmaCielo’s disclosed progress, capital markets activity and international initiatives in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PharmaCielo has achieved GMP certification from INVIMA for its Phytotherapeutics, confirming the quality of its cannabis extracts and proprietary cultivars. This certification enhances PharmaCielo's reputation as a leading producer in Colombia, with its Rionegro facility being one of the largest globally, processing 360 tonnes of biomass annually. The company aims to receive EU-GMP certification in H1-2022, having already complied with its standards since early 2021. Additionally, PharmaCielo has granted 1,375,000 Restricted Share Units and 550,000 stock options to directors and employees.